ArticleNews reportPHN-05642026-11-02 05:13 CT

DataMeds subsidiary secures peptide supply agreement By Investing.com

Source · Investing.com Canada

TLDR

DataMeds AI announced that subsidiary Corexa Health signed a commercial supply agreement covering six peptides. The company says Corexa Pharmacy plans to begin dispensing compounded prescriptions in November 2026; its release notes these drugs are not FDA-approved and have not been evaluated by FDA for safety or efficacy.

01—Key points

01The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
02The company attributes its planned dispensing to regulatory policy changes and FDA advisory committee recommendations.
03DataMeds says it plans to collect and report safety data through its mobile application.

Why it matters Editorial

The announcement concerns commercial expansion of peptide compounding while explicitly distinguishing these products from FDA-approved drugs.

Read the original at Investing.com Canada↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.